Fifteen protein targets are the stated scope of a multi-arm design campaign that Anthropic, PBC announced August 18, 2026, naming Twist Bioscience Corporation (Nasdaq: TWST) as one of its independent evaluators. The models powering the designs are Claude Opus 4.8 and Mythos Preview. Anthropic said it had already received binding data back from the campaign by the time the blog post published.
The filing mechanism matters here. Twist submitted an 8-K under Item 7.01, Regulation FD, a provision that requires companies to promptly disclose material third-party statements that mention them. Twist did not announce a contract. Anthropic's blog post named the South San Francisco company in a public disclosure, and Twist reported that fact to the SEC the same day, August 18.
Twist's assigned role, as Anthropic described it: rapidly produce AI-designed proteins at scale and test those designs for binding. That places Twist at the validation end of the workflow. The AI systems generate the candidate proteins; Twist produces them at scale and tests for binding.
The campaign ran across 15 targets using two AI tools. Anthropic described Twist as one of its independent evaluators, phrasing that implies additional laboratory counterparties without identifying them. The 8-K names no others.
No financial terms appear in the filing. The size of the production run, the per-unit economics, and any contracted value are not disclosed. The 8-K was signed by Judy Yan, Twist's Assistant General Counsel and Assistant Secretary.
Anthropic's full blog post is available at www.anthropic.com/research/Claude-accelerates-protein-design. Twist's filing carries the standard disclaimer that content on Anthropic's website is not incorporated by reference into the 8-K.
What the data shows when the full binding results are released is the remaining open question. Anthropic confirmed only that results are in hand.